Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Search Results

352 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Large-scale survey of rates of achieving targets for blood glucose, blood pressure, and lipids and prevalence of complications in type 2 diabetes (JDDM 40).
Yokoyama H, Oishi M, Takamura H, Yamasaki K, Shirabe SI, Uchida D, Sugimoto H, Kurihara Y, Araki SI, Maegawa H. Yokoyama H, et al. Among authors: uchida d. BMJ Open Diabetes Res Care. 2016 Oct 3;4(1):e000294. doi: 10.1136/bmjdrc-2016-000294. eCollection 2016. BMJ Open Diabetes Res Care. 2016. PMID: 27752329 Free PMC article.
Trends in glycemic control in patients with insulin therapy compared with non-insulin or no drugs in type 2 diabetes in Japan: a long-term view of real-world treatment between 2002 and 2018 (JDDM 66).
Yokoyama H, Araki SI, Yamazaki K, Kawai K, Shirabe SI, Oishi M, Kanatsuka A, Yagi N, Kabata D, Shintani A, Maegawa H; JDDM study group. Yokoyama H, et al. BMJ Open Diabetes Res Care. 2022 May;10(3):e002727. doi: 10.1136/bmjdrc-2021-002727. BMJ Open Diabetes Res Care. 2022. PMID: 35504696 Free PMC article.
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin compared with alpha-glucosidase inhibitor in Japanese patients with type 2 diabetes inadequately controlled on metformin or pioglitazone alone (Study for an Ultimate Combination Therapy to Control Diabetes with Sitagliptin-1): A multicenter, randomized, open-label, non-inferiority trial.
Yokoh H, Kobayashi K, Sato Y, Takemoto M, Uchida D, Kanatsuka A, Kuribayashi N, Terano T, Hashimoto N, Sakurai K, Hanaoka H, Ishikawa K, Onishi S, Yokote K. Yokoh H, et al. Among authors: uchida d. J Diabetes Investig. 2015 Mar;6(2):182-91. doi: 10.1111/jdi.12282. Epub 2014 Sep 24. J Diabetes Investig. 2015. PMID: 25802726 Free PMC article.
Efficacy and safety of ipragliflozin and metformin for visceral fat reduction in patients with type 2 diabetes receiving treatment with dipeptidyl peptidase-4 inhibitors in Japan: a study protocol for a prospective, multicentre, blinded-endpoint phase IV randomised controlled trial (PRIME-V study).
Koshizaka M, Ishikawa K, Ishikawa T, Kobayashi K, Takemoto M, Horikoshi T, Shimofusa R, Takahashi S, Nagashima K, Sato Y, Tatsuno I, Terano T, Hashimoto N, Kuribayashi N, Uchida D, Yokote K; PRIME-V Study Investigators. Koshizaka M, et al. Among authors: uchida d. BMJ Open. 2017 May 9;7(5):e015766. doi: 10.1136/bmjopen-2016-015766. BMJ Open. 2017. PMID: 28490565 Free PMC article. Clinical Trial.
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin compared with α-glucosidase inhibitor in Japanese patients with type 2 diabetes inadequately controlled on sulfonylurea alone (SUCCESS-2): a multicenter, randomized, open-label, non-inferiority trial.
Kobayashi K, Yokoh H, Sato Y, Takemoto M, Uchida D, Kanatsuka A, Kuribayashi N, Terano T, Hashimoto N, Sakurai K, Hanaoka H, Ishikawa K, Onishi S, Yokote K; SUCCESS Study Group. Kobayashi K, et al. Among authors: uchida d. Diabetes Obes Metab. 2014 Aug;16(8):761-5. doi: 10.1111/dom.12264. Epub 2014 Feb 18. Diabetes Obes Metab. 2014. PMID: 24447683 Clinical Trial.
Comparing the effects of ipragliflozin versus metformin on visceral fat reduction and metabolic dysfunction in Japanese patients with type 2 diabetes treated with sitagliptin: A prospective, multicentre, open-label, blinded-endpoint, randomized controlled study (PRIME-V study).
Koshizaka M, Ishikawa K, Ishibashi R, Maezawa Y, Sakamoto K, Uchida D, Nakamura S, Yamaga M, Yokoh H, Kobayashi A, Onishi S, Kobayashi K, Ogino J, Hashimoto N, Tokuyama H, Shimada F, Ohara E, Ishikawa T, Shoji M, Ide S, Ide K, Baba Y, Hattori A, Kitamoto T, Horikoshi T, Shimofusa R, Takahashi S, Nagashima K, Sato Y, Takemoto M, Newby LK, Yokote K; PRIME-V Study Group. Koshizaka M, et al. Among authors: uchida d. Diabetes Obes Metab. 2019 Aug;21(8):1990-1995. doi: 10.1111/dom.13750. Epub 2019 May 8. Diabetes Obes Metab. 2019. PMID: 30993861 Free PMC article. Clinical Trial.
Effects of ipragliflozin versus metformin in combination with sitagliptin on bone and muscle in Japanese patients with type 2 diabetes mellitus: Subanalysis of a prospective, randomized, controlled study (PRIME-V study).
Koshizaka M, Ishikawa K, Ishibashi R, Maezawa Y, Sakamoto K, Uchida D, Nakamura S, Yamaga M, Yokoh H, Kobayashi A, Onishi S, Kobayashi K, Ogino J, Hashimoto N, Tokuyama H, Shimada F, Ohara E, Ishikawa T, Shoji M, Ide S, Ide K, Baba Y, Hattori A, Kitamoto T, Horikoshi T, Shimofusa R, Takahashi S, Nagashima K, Sato Y, Takemoto M, Newby LK, Yokote K; PRIME-V study group. Koshizaka M, et al. Among authors: uchida d. J Diabetes Investig. 2021 Feb;12(2):200-206. doi: 10.1111/jdi.13340. Epub 2020 Aug 20. J Diabetes Investig. 2021. PMID: 32623839 Free PMC article. Clinical Trial.
352 results